Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women

Garrett Scott, Samuel C. Yiu, Daniel Wasilewski, Jonathan Song, Ronald E. Smith

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.

Original languageEnglish (US)
Pages (from-to)1109-1110
Number of pages2
JournalAmerican journal of ophthalmology
Volume139
Issue number6
DOIs
StatePublished - Jun 2005

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women'. Together they form a unique fingerprint.

  • Cite this